Quotient Bioscience Group, Ltd.: Series B $53M

Posted in I - Series B, Q - 3Q08, R - INTERNATIONAL, X - Diagnostic, X - Hematology

Quotient Bioscience Group (United Kingdom) a provider of bioscience analytics and safety evaluation services, closed a $53M Series B financing. Participants include TA Associates.

Sagent Pharmaceuticals, Inc.: Series A $83M

Posted in I - Series A, Q - 3Q08, R - MID WEST, X - Injectable, X - Therapeutic Platform

Sagent Pharmaceuticals (Schaumberg, Illinois) commercial-stage specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products, closed a $83M Series A financing. Participants include Vivo Ventures.

Pathwork Diagnostics, Inc.: Series B $20M

Posted in I - Series B, Q - 3Q08, R - WEST, X - Diagnostic, X - Oncology

Pathwork Diagnostics (Sunnyvale, CA) molecular diagnostics company focused on oncology, closed a $20M Series B financing. Participants include Abingworth, Advent Venture Partners, Novus Ventures, Prospect Venture Partners, Venrock and Versant Ventures.

VasoNova, Inc.: Series B $10M

Posted in I - Series B, Q - 3Q08, R - WEST, X - Device (Catheter)

VasoNova (Sunnyvale, CA) developer of a self-guided peripherally inserted central catheters, closed a $10M Series B financing. Participants include Arboretum Ventures, Aphelion Capital, Coronis Medical Ventures and Research Corporation Technologies, Coronis Medical Ventures and Life Science Angels.

ArKal Medical, Inc.: Series B $17.5

Posted in I - Series B, Q - 3Q08, R - WEST, X - Device (Diabetes), X - Device (Diagnostic)

ArKal Medical (Fremont, CA) developer of a continuous glucose monitoring system, closed a $17.5M Series B financing. Participants include Thomas McNerney & Partners, Delphi Ventures and MedVenture Associates.

Soteira, Inc.: Series B $12M

Posted in I - Series B, Q - 3Q08, R - NORTH EAST, X - Device (Spine)

Soteira (Natick, MA) developer of treatment for vertebral compression fractures, closed a $12M Series B financing. Participants include Delphi Ventures, Prism VentureWorks, Federated Kaufman Fund, HLM Venture Partners and Partech International.

Cocrystal Discovery, Inc.: Series A $10M

Posted in I - Series A, Q - 3Q08, R - NORTH WEST, X - Virology

Cocrystal Discovery (Seattle, WA) developer of antiviral therapeutics for the treatment of serious and chronic viral diseases, closed a $10M Series A financing. Participants include The Frost Group.

MonoSol Rx, Inc: Series C $10M

Posted in I - Series C, Q - 3Q08, R - NORTH EAST, X - Device (Delivery)

MonoSol Rx (Warren, NJ) drug delivery company specializing in the development and commercialization of thin film strip pharmaceutical drug products, closed a $10M Series C financing. Participants include Ed Bass Group, The Halifax Group, and CNF Investments.

Telormedix, SA: Series A $19M

Posted in I - Series A, Q - 3Q08, R - INTERNATIONAL, X - Immunology, X - Oncology

Telormedix (Switzerland) developer of immunotherapeutics for cancer, closed a $19M Series A financing. Participants include Aravis Ventures, Proquest Investments, BSI SA, Nextech Venture and Generali Insurance Group.

Lumavita, AG: Series A $16M

Posted in I - Series A, Q - 3Q08, R - INTERNATIONAL, X - Antiinfective, X - GYN

Lumavita (Switzerland) early-stage specialty biopharmaceutical company focused on antiinfectives for women’s health, closed a $16M Series A financing. Participants include Atlas Ventures, BB Biotech Ventures, and BioMedInvest.

Histogenics Corp.: Series B $9M

Posted in I - Series B, Q - 3Q08, R - NORTH EAST, X - Orthopedic, X - Stem Cell

Histogenics (Waltham, MA) early-stage cartilage regeneration company developing products for joint repair, closed a $9M Series B financing. Participants include Boston Millennia Partners, Foundation Medical Partners, Altima Partners, Stryker Corporation and Inflection Point Partners.

Osprey Pharmaceuticals, Inc: Series A $11M

Posted in I - Series A, Q - 3Q08, R - WEST, X - Inflammation

Osprey Pharmaceuticals (San Francisco, CA) early-stage company focused on protein therapeutics for treating inflammatory disease, closed a $11M Series A financing. Participants include Burrill & Co., Novo Nordisk Biotech Fund, Yasuda Enterprise Development, GeneChem Therapeutics Venture Fund, BDC Venture Capital and Western Technology Seed Investment Fund.

Spinifex Pharmaceuticals, Ltd.: Series B $12M

Posted in I - Series B, Q - 3Q08, R - INTERNATIONAL, X - Pain

Spinifex Pharmaceuticals (Australia) pain drug development company, closed a $12M Series B financing. Participants include GBS Venture Partners Limited, Brandon Capital Partners and Uniseed.

« Previous Entries

to top of page...